Immunome (IMNM) and Its Peers Head to Head Analysis

Immunome (NASDAQ:IMNM) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Immunome to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a breakdown of current ratings for Immunome and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1	1	14	0	2.81
Immunome Competitors	9903	15310	45655	1602	2.54

Immunome currently has a consensus target price of $33.85, indicating a potential upside of 80.32%. As a group, “Biotechnology” companies have a potential upside of 126.31%. Given Immunome’s competitors higher probable upside, analysts clearly believe Immunome has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

44.6% of Immunome shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Immunome and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Immunome	$6.94 million	-$212.39 million	-7.11
Immunome Competitors	$718.54 million	$11.20 million	-18.80

Immunome’s competitors have higher revenue and earnings than Immunome. Immunome is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Immunome has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. Comparatively, Immunome’s competitors have a beta of -1.88, suggesting that their average share price is 288% less volatile than the S&P 500.

Profitability

This table compares Immunome and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.33%	-47.63%
Immunome Competitors	-12,319.70%	-407.93%	-30.95%

Summary

Immunome competitors beat Immunome on 7 of the 13 factors compared.

Immunome Company Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.